Article: Nicotinamide Riboside Supplementation Benefits in Early Parkinson's Disease: Clinical Findings

Mar 1, 2022 Clinical Inflammation Neurological Health Parkinson's Disease

Nicotinamide Riboside Supplementation Benefits in Early Parkinson's Disease: Clinical Findings

Objectives

To assess the safety, tolerability, and cerebral penetration of NR therapy in Parkinson's disease (PD) patients, as well as determine if NR has an impact on their neurometabolic profile and motor symptoms.

Journal

Cell Metabolism

Key Outcomes

NR supplementation significantly increased cerebral NAD+ levels, altered brain metabolic pattern, and decreased levels of inflammatory cytokines in the cerebrospinal fluid of PD patients.
Moreover, patients experienced a mild but significant clinical improvement, and this correlated with the change in the brain's metabolic pattern.

Duration

30 days

Dose

1000 mg

Study Design

Randomized, double-blind, placebo-controlled, phase I study in 30 Parkinson's disease (PD) patients

See Published Study

Neurological Health

Nicotinamide Riboside Reduces Chemotherapy-Induced Eye and Body Hypersensitivity: Preclinical Findings

SynopsisChemotherapy often causes dry eye and nerve pain, which may be due to nerve damage. This study treated rats given the chemotherapy drug paclitaxel with nicotinamide riboside (NR). Paclitaxe...

Metabolic Health

DNA Replication Stress Causes Complex Metabolic Changes: Preclinical Findings

SynopsisDNA replication stress occurs when cells struggle to copy damaged DNA, affecting metabolism. Using mice lacking the DNA polymerase Rev1, researchers observed sex-specific metabolic changes:...